• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>NCI

NCI

  1. FDA Grants “Fast Track” Status to Cancer Prevention Pharmaceuticals’ Lead Drug CPP-1X/sul for Treatment of Familial Adenomatous Polyposis

    FDA Grants “Fast Track” Status to Cancer Prevention Pharmaceuticals’ Lead Drug CPP-1X/sul for Treatment of Familial Adenomatous Polyposis

  2. Moderna Announces Pipeline and Corporate Update

    Moderna Announces Pipeline and Corporate Update

  3. Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017

    Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017

  4. Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017

    Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017

12345

©2017 Morningstar Advisor. All right reserved.